
Adding methotrexate to adalimumab (Humira, AbbVie) in axial spondyloarthritis was associated with reduced immunogenicity, and prolonged co-medication was associated with long-term maintenance of adalimumab, say researchers recently writing in RMD Open: Rheumatic & Musculoskeletal Diseases.




























